AIA
ALLO icon

Arcadia Investment Advisors’s Allogene Therapeutics ALLO Stock Holding History

Arcadia Investment Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$32 Hold
20
– – ﹤0.01% 86
2026
Q2 		$42 Hold
20
– – ﹤0.01% 79
2026
Q1 		$49 Hold
20
– – ﹤0.01% 80
2025
Q4 		$28 Hold
20
– – ﹤0.01% 81
2025
Q3 		$25 Hold
20
– – ﹤0.01% 82
2025
Q2 		$23 Hold
20
– – ﹤0.01% 83
2025
Q1 		$30 Hold
20
– – ﹤0.01% 79
2024
Q4 		$43 Hold
20
– – ﹤0.01% 79
2024
Q3 		$56 Hold
20
– – ﹤0.01% 76
2024
Q2 		$47 Hold
20
– – ﹤0.01% 77
2024
Q1 		$90 Buy
+20
New +$83 ﹤0.01% 75

Other funds holding ALLO

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.52B AUM 21.45% 1-Year Est. Return
TC
Trust Company Manhattan, Kansas $1.15B AUM 7.83% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Arcadia Investment Advisors's ALLO Position: Q3 2026 in Review

Arcadia Investment Advisors held its Allogene Therapeutics (ALLO) position steady in Q3 2026 at 20 shares worth $32. The position accounts for ﹤0.01% of the portfolio, ranked #86.

Arcadia Investment Advisors first reported a position in ALLO in Q1 2024 and has held it in 11 quarters since. The position peaked at $90 in Q1 2024. 7 funds tracked by Wall St. Rank hold ALLO as of Q3 2026.

  • Arcadia Investment Advisors held 20 shares of Allogene Therapeutics worth $32 as of Q3 2026.
  • Arcadia Investment Advisors left its Allogene Therapeutics share count unchanged in Q3 2026.
  • Allogene Therapeutics made up ﹤0.01% of Arcadia Investment Advisors's portfolio in Q3 2026, its #86 holding.
  • Arcadia Investment Advisors first reported a position in Allogene Therapeutics in Q1 2024 and has held it in 11 quarters since.
  • Arcadia Investment Advisors's Allogene Therapeutics position peaked at $90 in Q1 2024.
  • 7 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2026.

Based on Arcadia Investment Advisors's 13F filing for Q3 2026, filed 13 Oct 2026.